Jyseleca (filgotinib) / Galapagos, Gilead, Eisai, SOBI, Alfasigma - LARVOL DELTA

Filgotinib treatment modulates frequency and gene expression of circulating immune cell subsets in ulcerative colitis. (PubMed, J Crohns Colitis) - "Filgotinib response was associated with normalization of the cellular frequency and gene expression levels of B cells and phagocytic mononuclear cells in UC patients, resulting in immune profiles resembling those of healthy controls."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab. (PubMed, Biologics) - "Case 1: A 53-year-old man with steroid-dependent UC achieved rapid symptomatic improvement and complete mucosal healing on upadacitinib...Case 2: A 36-year-old woman with refractory UC achieved clinical remission and mucosal healing with filgotinib following inadequate response to vedolizumab and corticosteroids...These cases suggest that a positive switch may be a reasonable option for patients who respond to JAK inhibitors but have concerns about long-term safety. Additional cases are required to better define the clinical role of this strategy."

Journal • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Respiratory Diseases • Thrombosis • Ulcerative Colitis • Varicella Zoster

Janus Kinase Inhibitors for Alopecia Universalis: A Systematic Review (AAD 2026) - "Tofacitinib was most frequently used (222 cases; mean 10.4 months), followed by deuruxolitinib (53), baricitinib (20), ruxolitinib (19), upadacitinib (8), ritlecitinib (4), abrocitinib (2), and filgotinib (1)... JAKi are promising for AU, with tofacitinib demonstrating the most consistent regrowth. Evidence is limited, and larger trials are needed to confirm efficacy and safety."

Review • Alopecia • CNS Disorders • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Multiple Sclerosis • Varicella Zoster

Advances in the use of Janus kinase inhibitors. (PubMed, Curr Opin Rheumatol) - "Increased use of JAKi in the management of IMIDs is ongoing and will accelerate if the positive results noted in trials for lupus, inflammatory myopathies, and psoriatic arthritis result in regulatory approval. The article highlighted in this review provide an update on the progress being made in newer rheumatic disease indications as well as efforts to better understand the adverse event profile for patients on treatment."

Journal • Ankylosing Spondylitis • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Giant Cell Arteritis • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Myositis • Oncology • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Venous Thromboembolism • TYK2

Integrated Safety Analysis of Filgotinib in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Over a Treatment Duration of up to 5 Years. (PubMed, Mod Rheumatol) - P3 | "Long-term filgotinib treatment was well tolerated at 200 mg and 100 mg in Japanese patients with RA over up to 5 years, confirming previous global analyses."

Journal • Cardiovascular • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Varicella Zoster

Cardiovascular risk and JAK inhibitor for the treatment of spondyloarthritis: A systematic review. (PubMed, Tunis Med) - "This systemic review highlights the safety of JAK inhibitors according to MACE occurrence in patients with SpA when compared to placebo. These results need to be interpreted with caution regarding the limited long-term data and small sample sizes in clinical trials. Long-term studies are needed to clarify these risks."

Journal • Review • Ankylosing Spondylitis • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Immunology • Myocardial Infarction • Seronegative Spondyloarthropathies • Spondylarthritis

Short-term effects of Filgotinib versus Adalimumab on bone microarchitecture in rheumatoid arthritis, 24-week results of a randomized clinical trial (EULAR 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Switching to Filgotinib is Non-inferior to Add-on Therapy for Improvement of Disease Activity at Week 24 in Methotrexate–Inadequate Responders with Rheumatoid Arthritis: The FAITHFUL Randomised Non-inferiority Trial (EULAR 2026) - No abstract available

Clinical • Head-to-Head • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Safety and Treatment Persistence of Filgotinib in Patients with Rheumatoid Arthritis: Results from the Multicentre SOFIA study (Observational Study on the Safety of Filgotinib in Rheumatoid Arthritis) (EULAR 2026) - No abstract available

Clinical • Observational data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: Final results of the FINCH 4 long-term extension study (EULAR 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Improvement in patient-reported outcomes (PROs) with filgotinib by prior advanced therapy in patents with rheumatoid arthritis: Interim results from the FILOSOPHY and PARROTFISH real-world studies (EULAR 2026) - No abstract available

Clinical • Metastases • Patient reported outcomes • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Consistent long-term safety of filgotinib in rheumatoid arthritis over a median of 4.8 years: Integrated evidence from seven clinical trials (EULAR 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

First results of the DRIMID study : a multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in idiopathic inflammatory myopathies (EULAR 2026) - No abstract available

Clinical • P2 data • Myositis

Impact of filgotinib on MRI inflammatory and structural lesions in the sacroiliac joint of patients with axial spondyloarthritis: 52-week results from the Phase 3 OLINGUITO trial (EULAR 2026) - No abstract available

Clinical • P3 data • Ankylosing Spondylitis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis

Filgotinib significantly improves disease activity in patients with active axial spondyloarthritis: Primary results from the Phase 3 OLINGUITO trial (EULAR 2026) - No abstract available

Clinical • P3 data • Ankylosing Spondylitis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis

Impact of filgotinib on health-related quality of life over 3 years in Japanese patients with ulcerative colitis: a post hoc analysis of the SELECTION and SELECTION long-term extension trials. (PubMed, Intest Res) - P2b, P3 | "MCID rates were maintained in completers up to 3 years and increased notably in non-responders (except WPAI absenteeism and EQ-5D) from week 10 to years 1-3. FIL200 treatment was associated with sustained improvements in HRQoL and work productivity over 3 years in Japanese patients with ulcerative colitis, consistent with the overall SELECTION and SELECTIONLTE trial populations."

HEOR • Journal • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

SELECTIONLTE: Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (clinicaltrials.gov) - P3 | N=1000 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

SELECTIONLTE: Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (clinicaltrials.gov) - P3 | N=1173 | Active, not recruiting | Sponsor: Galapagos NV

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Proteomic discordance with clinical and biochemical response filgotinib in Ulcerative Colitis suggests residual inflammatory signals (ECCO-IBD 2026) - "These data should be corroborated using tissue-resolved endpoints in the inflamed mucosa, alongside peripheral immunophenotyping to map compartment-specific effects. If validated, proteomic readouts could refine treat-to-target strategies beyond CRP and fecal calprotectin, and clarify whether JAK1 inhibition primarily suppresses symptom-generating downstream signalling or achieves deeper resolution of mucosal immune activity."

Clinical • Discordant • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CCL18 • CRP • IL18 • JAK1 • LGALS1 • TNFRSF1A

JAK inhibitors versus anti-IL12/23 agents as third-line therapy in refractory Ulcerative Colitis: an international multi-centre study (3D-UC) (ECCO-IBD 2026) - "In practice, vedolizumab 2 , JAK inhibitors(JAKi) 3 , and IL-12/23 inhibitors are used sequentially 4 , with IL-12/23 or JAKi often reserved for third-line therapy 4...Patients were treated with mirikizumab, ustekinumab, upadacitinib, filgotinib and tofacitinib...In the anti-IL12/23 cohort, 1 patient developed infectious endocarditis, while 2 cases of lymphoma and basal cell carcinoma were reported among JAKi. Conclusion JAKi demonstrated superior clinical response rates at week 12 as third line therapy versus anti-IL12/23, with upadacitinib achieving higher, but not statistically significant, remission rates."

Clinical • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A

Sequencing Patterns and Efficacy of Biological Therapies and Small Molecules in Patients with Ulcerative Colitis: A Single-Center Retrospective Study (ECCO-IBD 2026) - "Patients underwent 78 courses of advanced therapy (Infliximab 30, Adalimumab 11, Golimumab 8, Vedolizumab 22, Ustekinumab 1, Tofacitinib 2, Filgotinib 2, Ozanimod 2). Conclusion Advanced biologic and small-molecule therapies were effective and generally well-tolerated in patients with refractory UC. Infliximab showed the most durable first-line treatment response, whereas Adalimumab was associated with a shorter treatment duration."

Retrospective data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Effect of JAK inhibitors on extra-intestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease (ECCO-IBD 2026) - "Methods This multicentric retrospective cohort included adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) who initiated a JAK inhibitor (tofacitinib, upadacitinib or filgotinib) for IBD and had at least one EIM or IMID. Conclusion JAK inhibitors demonstrated effectiveness for IBD activity and associated EIMs/IMIDs, with particularly robust responses in peripheral SpA and more variable outcomes in dermatological manifestations. New-onset EIMs/IMIDs were uncommon."

Clinical • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

FINCH 4: Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis (clinicaltrials.gov) - P3 | N=2800 | Enrolling by invitation | Sponsor: Gilead Sciences | Trial completion date: Sep 2023 ➔ Apr 2022 | Trial primary completion date: Nov 2020 ➔ Apr 2022

Trial completion date • Trial primary completion date • Immunology • Rheumatoid Arthritis

Comparison of effectiveness between Vedolizumab and Filgotinib in patients with ulcerative colitis previously exposed to at least one anti-TNF agent: Results from the real-world evidence multicenter VEDOFIL study (ECCO-IBD 2026) - "Conclusion In this real-world evidence study, VDZ appeared to be a more effective option than FLG as a second-line biologic (after anti-TNF failure), whereas FLG became a better option in third- or fourth-line of advanced therapies. These data may help physicians managing patients with UC to guide therapeutic decision-making."

Clinical • HEOR • Real-world • Real-world evidence • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Effectiveness and safety of switching from a first JAKi to a subsequent JAKi in patients with ulcerative colitis: preliminary retrospective data from IG-IBD multicentre cohort study (ECCO-IBD 2026) - "Tofacitinib was the most common first JAKi (48, 69.6%) prescribed; among those who switched from tofacitinib, 9 (24.3%) moved to filgotinib and 28 (75.7%) to upadacitinib. Six patients experienced adverse drug reactions, none leading to discontinuation Conclusion Our preliminary findings suggest that switching from a first to a subsequent JAKi is effective and safe, including for patients with prior exposure to multiple biologic therapies. Further retrospective and prospective analyses will provide more precise estimates"

Retrospective data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis